Idera Pharmaceuticals (IDRA) Posts Q2 Loss of 23c, Beats Views
Tweet
Share
E-mailGet Alerts IDRA Hot Sheet
Join SI Premium – FREE
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) reported Q2 EPS of ($0.23), $0.02 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $33 thousand versus the consensus estimate of $4.4 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
- Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
